uniQure Deal History & Licensing Activity
uniQure is a biotech headquartered in Netherlands. Over the past three years, uniQure has been involved in 10 licensing and acquisition transactions, with a primary focus on Gene Therapy (14 deals). The company currently has 5 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
5
Top Modality
Gene Therapy
Focus Area
Rare Disease
uniQure Recent Deal Activity
Licensing, acquisition, and partnership transactions involving uniQure in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| etranacogene dezaparvovec (Hemgenix) | CSL Behring | Gene Therapy | Approved | license | Apr 2026 |
| etranacogene dezaparvovec | CSL Behring | Gene Therapy | Approved | license | Apr 2026 |
| etranacogene dezaparvovec (Hemgenix) | CSL Behring | Gene Therapy | Approved | license | Apr 2026 |
uniQure Pipeline Focus
Therapeutic areas and modalities where uniQure is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
uniQure Strategic Signals
Key indicators of uniQure's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
uniQure Clinical Pipeline
uniQure has 5 active clinical trials across 1 development phase.
5
Phase 1
See How Your Asset Matches uniQure's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About uniQure Licensing & Deal Activity
uniQure is a biotech company based in Netherlands that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, uniQure ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for uniQure include Rare Disease (11 deals and trials), CNS Disorders (4 deals and trials), Hematology (3 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, uniQure has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for uniQure and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against uniQure's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.